Core Team
Thomas Stackhouse
Thomas M. Stackhouse, Ph.D.
Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Dr. Stackhouse is the Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute, NIH. In this position, Dr. Stackhouse oversees the patent portfolio and marketing activities for the National Cancer Institute, including its Frederick Maryland campus and the newly formed Frederick National Laboratory for Cancer Research (FNL)
In addition, Dr. Stackhouse leads the TTC staff by coordinating intellectual property parameters and guidelines for several key NCI initiatives including NCI’s Alliance for Nanotechnology in Cancer and the NCI Chemical Biology Consortium. Dr. Stackhouse works closely with state and local economic development groups to foster new partnerships which facilitate the use of NCI technologies and expertise to advance the pubic health and stimulate the nation’s economies. Dr. Stackhouse is Vice Chair of the Education and Training Committee of the Federal Laboratory Consortium (FLC) and an elected member the Executive Board of the FLC
Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his Ph.D. in Biochemistry from the University of California, Davis. Dr. Stackhouse spent several years as a Developmental Scientist for a major pharmaceutical company and later was part of the research team who discovered the VHL tumor suppressor gene. Dr. Stackhouse has received several awards including the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer Office and the FLC Mid-Atlantic Technology Transfer Representative of the Year
Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Dr. Stackhouse is the Associate Director for the Technology Transfer Center (TTC) at the National Cancer Institute, NIH. In this position, Dr. Stackhouse oversees the patent portfolio and marketing activities for the National Cancer Institute, including its Frederick Maryland campus and the newly formed Frederick National Laboratory for Cancer Research (FNL)
In addition, Dr. Stackhouse leads the TTC staff by coordinating intellectual property parameters and guidelines for several key NCI initiatives including NCI’s Alliance for Nanotechnology in Cancer and the NCI Chemical Biology Consortium. Dr. Stackhouse works closely with state and local economic development groups to foster new partnerships which facilitate the use of NCI technologies and expertise to advance the pubic health and stimulate the nation’s economies. Dr. Stackhouse is Vice Chair of the Education and Training Committee of the Federal Laboratory Consortium (FLC) and an elected member the Executive Board of the FLC
Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his Ph.D. in Biochemistry from the University of California, Davis. Dr. Stackhouse spent several years as a Developmental Scientist for a major pharmaceutical company and later was part of the research team who discovered the VHL tumor suppressor gene. Dr. Stackhouse has received several awards including the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer Office and the FLC Mid-Atlantic Technology Transfer Representative of the Year
Jonathan Lui
Jonathan Lui
Managing Director, The Center for Advancing Innovation, INC.
Jonathan has worked on a variety of portfolio strategy, operational optimization and business strategy engagements. When a problem is labeled "impossible," he's charged with solving it, which he has done with grace and poise. He has worked with the following client efforts: Novartis, Glaxo Smith Kline and several others. For example, he led an engagement to assess one large pharma's suite of clinical trials; identified ways to make them more successful and also generated financial models to illustrate the value of pursuing recommendations. Jonathan has also been the lead due diligence consultant on a portfolio strategy engagement for an infectious disease drug, device and diagnostic company, where the team identified a large exist as well as a bootstrap strategy to mitigate risk for potential investors
Managing Director, The Center for Advancing Innovation, INC.
Jonathan has worked on a variety of portfolio strategy, operational optimization and business strategy engagements. When a problem is labeled "impossible," he's charged with solving it, which he has done with grace and poise. He has worked with the following client efforts: Novartis, Glaxo Smith Kline and several others. For example, he led an engagement to assess one large pharma's suite of clinical trials; identified ways to make them more successful and also generated financial models to illustrate the value of pursuing recommendations. Jonathan has also been the lead due diligence consultant on a portfolio strategy engagement for an infectious disease drug, device and diagnostic company, where the team identified a large exist as well as a bootstrap strategy to mitigate risk for potential investors
Rosemarie Truman
Rosemarie Truman
Founder, The Center for Advancing Innovation, INC.
Rosemarie has over 20 years of experience in driving growth for clients, having created over $21 billion in new profits for clients that launched over 100 new products/services/solutions. Her experience spans strategy consulting, investment banking, and entrepreneurship. Rosemarie has provided strategy consulting services for over 110 clients in over 15 countries and 24 states. Having started her career at Goldman Sachs as an analyst, to this day, Rosemarie's core competencies are in complex due diligence and portfolio strategy, creating sustainable growth breakthrough strategies for clients and transformation
Currently, Ms. Truman is founder and CEO of a global public-private partnership whose mission is to accelerate and increase the volume of technology transfer, translational research and commercialization. Her firm, The Center for Advancing Innovation, has been working with the Avon Foundation on Portfolio Strategy and also has Partnership Intermediary agreements with the National Institutes of Health, National Cancer Institute, the National Heart, Lung and Blood Institute and six other research institutes within the NIH. With the NIH, CDC, and the Heritage provider network, her firm is serving as managing director of a first-of-a-kind national business plan and startup Challenge for select brain focused inventions
Prior to launching her own firm, Rosemarie served as the global leader of IBM and PRTM's Innovation and R&D strategy practice; the VP and head of global strategy at Marsh & McLennan; leader in Oracle's Advanced Technology Group and also led eBusiness Strategy while at Ernst & Young. At IBM, Rosemarie also led internal transformation efforts in the Emerging Business Opportunity area to create models that drive sustainable "growth breakthroughs." Finally, Rosemarie has spearheaded the development of several trade secret models, frameworks and to select and nurture sustainable growth opportunities; one model is for the Life Sciences industry called "Industry Leading R&D Performance"
Founder, The Center for Advancing Innovation, INC.
Rosemarie has over 20 years of experience in driving growth for clients, having created over $21 billion in new profits for clients that launched over 100 new products/services/solutions. Her experience spans strategy consulting, investment banking, and entrepreneurship. Rosemarie has provided strategy consulting services for over 110 clients in over 15 countries and 24 states. Having started her career at Goldman Sachs as an analyst, to this day, Rosemarie's core competencies are in complex due diligence and portfolio strategy, creating sustainable growth breakthrough strategies for clients and transformation
Currently, Ms. Truman is founder and CEO of a global public-private partnership whose mission is to accelerate and increase the volume of technology transfer, translational research and commercialization. Her firm, The Center for Advancing Innovation, has been working with the Avon Foundation on Portfolio Strategy and also has Partnership Intermediary agreements with the National Institutes of Health, National Cancer Institute, the National Heart, Lung and Blood Institute and six other research institutes within the NIH. With the NIH, CDC, and the Heritage provider network, her firm is serving as managing director of a first-of-a-kind national business plan and startup Challenge for select brain focused inventions
Prior to launching her own firm, Rosemarie served as the global leader of IBM and PRTM's Innovation and R&D strategy practice; the VP and head of global strategy at Marsh & McLennan; leader in Oracle's Advanced Technology Group and also led eBusiness Strategy while at Ernst & Young. At IBM, Rosemarie also led internal transformation efforts in the Emerging Business Opportunity area to create models that drive sustainable "growth breakthroughs." Finally, Rosemarie has spearheaded the development of several trade secret models, frameworks and to select and nurture sustainable growth opportunities; one model is for the Life Sciences industry called "Industry Leading R&D Performance"
Kathleen Higinbotham, M.S., M.B.A.
Kathleen Higinbotham, M.S., M.B.A.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Kathy received a B.S. degree in Biology from James Madison University in Harrisonburg, VA, an M.S. degree in Biomedical Science from Hood College in Frederick, MD, and an M.B.A. degree with concentrations in Marketing and Management from Mount St. Mary's University in Emmitsburg, MD.
She was a Biologist at the National Cancer Institute in the research areas of tumor biology and kidney development before joining the NCI Technology Transfer Center (TTC) in May 2000. As a Technology Transfer Specialist, she negotiates transactional agreements like MTAs, CDAs and CRADAs for NCI and the Frederick National Laboratory, including the Nanotechnology Characterization Laboratory, as well as manages NCI’s intellectual property. Her experience in Technology Transfer, including several years in a Competitive Service Center, has been broad, having served investigators from several different NIH institutes on the Bethesda, Baltimore and Frederick campuses and having been involved in several NIH-wide initiatives.
She is now stationed in the Frederick office of TTC and has a special interest in working with the local and state business community including the Frederick County Business Incubator (FITCI), the Frederick County Office of Economic Development, TEDCO and the Maryland Technology Council to help establish partnerships that will result in the further development of NCI technology.
Technology Transfer Specialist, the Technology Transfer Center (TTC) at the National Cancer Institute (NCI)
Kathy received a B.S. degree in Biology from James Madison University in Harrisonburg, VA, an M.S. degree in Biomedical Science from Hood College in Frederick, MD, and an M.B.A. degree with concentrations in Marketing and Management from Mount St. Mary's University in Emmitsburg, MD.
She was a Biologist at the National Cancer Institute in the research areas of tumor biology and kidney development before joining the NCI Technology Transfer Center (TTC) in May 2000. As a Technology Transfer Specialist, she negotiates transactional agreements like MTAs, CDAs and CRADAs for NCI and the Frederick National Laboratory, including the Nanotechnology Characterization Laboratory, as well as manages NCI’s intellectual property. Her experience in Technology Transfer, including several years in a Competitive Service Center, has been broad, having served investigators from several different NIH institutes on the Bethesda, Baltimore and Frederick campuses and having been involved in several NIH-wide initiatives.
She is now stationed in the Frederick office of TTC and has a special interest in working with the local and state business community including the Frederick County Business Incubator (FITCI), the Frederick County Office of Economic Development, TEDCO and the Maryland Technology Council to help establish partnerships that will result in the further development of NCI technology.
Uma Prabhakar, Ph.D.
Uma Prabhakar, Ph.D.
Advisory, the National Cancer Institute (NCI)
Dr. Uma Prabhakar holds an Advisory position at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in Bethesda, where she is primarily responsible for enhancing the translation of NCI’s Alliance for Nanotechnology, an ongoing initiative to evaluate a promising technology platform toward breakthrough applications and potential treatments for Cancer. She recently established a public private partnership between industry and academia (TONIC) to promote advancements in nanotechnology translation. Previously, Uma served as Vice President of a Contract Research Organization, Frontage Laboratories, where she created and established a new service line franchise focused on outsourcing bio-analytical services and assay development & validation of biologics and biomarkers for priority customers. Prior to that, Uma had 27 years of industrial experience in both discovery research and clinical pharmacology where she held various leadership positions at Glaxo Smith Kline and Centocor, a Johnson & Johnson Company, including that of Senior Director in Oncology Biomarkers and Translational Medicine and Clinical Pharmacology. Her expertise spans across preclinical GLP and clinical Phase I-IV stages of drug development. She has made contributions to the immunogenicity and pharamcodynamic characterization of brand-name drugs such as Remicade®, Simponi®, Stelara® and Siltuximab. She is also a co-founder and senior advisor of a start-up biotech company, BRIM Biotechnology Inc., based in Taiwan. Uma holds a Ph.D in Human Genetics from Osmania University in Hyderabad, India.
Advisory, the National Cancer Institute (NCI)
Dr. Uma Prabhakar holds an Advisory position at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in Bethesda, where she is primarily responsible for enhancing the translation of NCI’s Alliance for Nanotechnology, an ongoing initiative to evaluate a promising technology platform toward breakthrough applications and potential treatments for Cancer. She recently established a public private partnership between industry and academia (TONIC) to promote advancements in nanotechnology translation. Previously, Uma served as Vice President of a Contract Research Organization, Frontage Laboratories, where she created and established a new service line franchise focused on outsourcing bio-analytical services and assay development & validation of biologics and biomarkers for priority customers. Prior to that, Uma had 27 years of industrial experience in both discovery research and clinical pharmacology where she held various leadership positions at Glaxo Smith Kline and Centocor, a Johnson & Johnson Company, including that of Senior Director in Oncology Biomarkers and Translational Medicine and Clinical Pharmacology. Her expertise spans across preclinical GLP and clinical Phase I-IV stages of drug development. She has made contributions to the immunogenicity and pharamcodynamic characterization of brand-name drugs such as Remicade®, Simponi®, Stelara® and Siltuximab. She is also a co-founder and senior advisor of a start-up biotech company, BRIM Biotechnology Inc., based in Taiwan. Uma holds a Ph.D in Human Genetics from Osmania University in Hyderabad, India.
Michele Newton
Michele Newton
Marketing Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Michele Newton is a marketing specialist at the National Cancer Institute’s (NCI) Technology Transfer Center (TTC). In this position, Michele supports TTC’s marketing efforts to facilitate partnerships to accelerate the development of the NCI patent portfolio. Prior to NCI, Michele was the North America regional marketing manager for JDSU, a leading provider of optical products and test and measurement solutions for the communications industry. In that role, Michele lead the strategic planning and implementation of targeted communication programs for JDSU’s North American communications test and measurement market. In spring 2014, Michele was a faculty member and presenter at EXHIBITOR 2014, a professional conference that champions best practices in trade shows and events. Michele is also a supporting contributor to the Breast Cancer Startup Challenge team. She received her BA in Journalism and Public Relations from Indiana University of Pennsylvania.
Marketing Specialist, the Technology Transfer Center (TTC) at the NIH National Cancer Institute (NCI)
Michele Newton is a marketing specialist at the National Cancer Institute’s (NCI) Technology Transfer Center (TTC). In this position, Michele supports TTC’s marketing efforts to facilitate partnerships to accelerate the development of the NCI patent portfolio. Prior to NCI, Michele was the North America regional marketing manager for JDSU, a leading provider of optical products and test and measurement solutions for the communications industry. In that role, Michele lead the strategic planning and implementation of targeted communication programs for JDSU’s North American communications test and measurement market. In spring 2014, Michele was a faculty member and presenter at EXHIBITOR 2014, a professional conference that champions best practices in trade shows and events. Michele is also a supporting contributor to the Breast Cancer Startup Challenge team. She received her BA in Journalism and Public Relations from Indiana University of Pennsylvania.
